Therefore, Kalorama is now offering selections from the neurotherapeutics study, covering each of these topics in turn, while at the same time providing selected overall findings in other disease areas to allow for comparison and context. The selections provide the study’s full results in the specific area and the general context and strategic implications from the full study, all at a fraction of the cost.
Among the selections, you’ll find:
I. Executive Summary (15 pages) —Included in this selection is the complete executive summary from the full neurotherapeutics report, providing you with an overview of the entire neurotherapeutics market and top-level numbers on such neurological diseases as peripheral neuropathy, Parkinson’s disease, and Alzheimer’s disease, among others for the top seven world markets. The executive summary outlines the context of the entire neurology market and how MS therapeutics fit in.
II. Introduction (3 pages) —Selection includes the overview of MS, including prevalence estimates.
III. Treatment (11 pages) —This selection reviews current treatment protocols and the agents used in relapsing-remitting MS, secondary-progressive MS, and other forms of MS.
IV. Progress and Promise in Therapeutic Development (27 pages) —Because progress on other neurotherapeutic fronts can have significant impact on MS therapeutics, information about all of the developments in neurogenomics and neural implants that the full study covered are included in this selection. Information specific to MS includes Table 4-11: Active Clinical Trials Involving Multiple Sclerosis.
V. World Market Analysis (28 pages, including 10 tables and 4 figures) —Selection provides complete market projections and growth rates for MS therapeutics in each of the top world markets. Growth rates for MS markets and those of other major neurological diseases are included, along with total world numbers for comparison.
VI. Company Profiles (31 pages) —Profiles of the following companies are included:
VII. Conclusions and Strategic Implications (9 pages) —This selection represents all of the analyst’s conclusions from the neurotherapeutics study as a whole, spelling out seven main conclusions and what they mean for developers and marketers of neurotherapeutic agents.
VIII. Glossary (8 pages)
IX. Company Directory (8 pages)
Or leave us a message and we'll call you back!
Receive bi-weekly email alerts for new market research.